Background: Currently, first-line chemotherapy in advanced colorectal cancer is not tailored on predictive biomarkers. Bax proapoptotic protein may correlate to chemosensitivity and differential response to irinotecan or oxaliplatin-based combinations. Methods: Bax expression was assessed by immunohistochemistry in 49 advanced colorectal cancer patients enrolled at our institution from 2002 to 2004 within a multicenter, phase II, randomized trial of first-line UFT/leucovorin/irinotecan (TEGAFIRI) versus UFT/leucovorin/ oxaliplatin (TEGAFOX). Results: Bax-positive and negative samples were 49 and 51 %. Response was significantly lower in Bax positive (25 %) as compared to Bax negative (56 %) (Odds ratio = 0.26; p = 0.03). No significant difference was noted in TEGAFOX subgroup; in TEGAFIRI arm, responses were lower in Bax positive (18 %) than Bax negative (67 %) (Odds ratio = 0.11; p = 0.03). No difference in terms of progression-free and overall survival was observed according to Bax. Conclusion: Bax-negative colorectal cancer may identify a specific phenotype of patients with significantly higher chance to respond to doublet irinotecan-based chemotherapy.
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients / F. Pietrantonio, P. Biondani, M. Milione, F. Melotti, G. Bertarelli, F. Perrone, F. De Braud, L. Mariani, G. Fanetti, D. Cortinovis, M. Di Bartolomeo. - In: CLINICAL & TRANSLATIONAL ONCOLOGY.. - ISSN 1699-048X. - 15:7(2013 Jul), pp. 582-586.
|Titolo:||Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients|
PIETRANTONIO, FILIPPO (Corresponding)
BIONDANI, PAMELA (Secondo)
CORTINOVIS, DIEGO LUIGI (Penultimo)
|Parole Chiave:||Bax; biomarkers; chemotherapy; colorectal cancer; irinotecan; adult; aged; antineoplastic agents; camptothecin; colorectal neoplasms; disease-free survival; female; humans; immunohistochemistry; leucovorin; male; middle aged; bcl-2-associated x protein; oncology; cancer research|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||lug-2013|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s12094-012-0971-3|
|Appare nelle tipologie:||01 - Articolo su periodico|